• AbbVie recently announced that the European Commission approved RINVOQ (upadacitinib, 15 mg once daily) as the first systemic therapy in the EU for non-segmental vitiligo in patients 12 years and older who are candidates for systemic treatment.
• This decision expands AbbVie’s immunology footprint into an area of high unmet need, potentially enhancing the clinical and commercial profile of RINVOQ across dermatology.
• We’ll now examine how RINVOQ’s new European non-segmental vitiligo approval may influence AbbVie’s broader investment narrative and pipeline-driven outlook.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

AbbVie Investment Narrative Recap

To own AbbVie, I think you have to believe in its ability to replace HUMIRA over time with a broader immunology and oncology portfolio, while funding growth and a sizable dividend from a concentrated set of blockbusters. The new EU RINVOQ approval in non-segmental vitiligo enhances that replacement story but does not change the key near term catalyst, which is execution on RINVOQ and SKYRIZI growth, nor the biggest risk around pricing pressure and eventual biosimilar competition.

Among recent announcements, the planned US$10.9 billion acquisition of Apogee Therapeutics stands out alongside this RINVOQ label expansion, as both speak to how AbbVie is leaning into immunology to refresh and extend its growth drivers beyond HUMIRA. Together, the vitiligo approval and pipeline additions reinforce how much of AbbVie’s investment case now rests on continued innovation and diversification across immunology indications.

However, while these approvals are encouraging, investors should also be aware that...

AbbVie's narrative projects $79.2 billion revenue and $23.1 billion earnings by 2029. This requires 8.0% yearly revenue growth and about a $19.5 billion earnings increase from $3.6 billion today.

Uncover how AbbVie's forecasts yield a $266.89 fair value, in line with its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community currently see AbbVie's fair value between US$266.89 and US$465.10, underscoring how far apart individual estimates can be. Against that backdrop, the growing dependence on a concentrated immunology and neuroscience portfolio means you may want to compare these views with the risks around future patent expiries and pricing pressure.

Explore 3 other fair value estimates on AbbVie - why the stock might be worth as much as 77% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AbbVie research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free AbbVie research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbbVie's overall financial health at a glance.

Seeking Other Investments?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 49 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.